Page last updated: 2024-10-28

ibudilast and Allergic Encephalomyelitis

ibudilast has been researched along with Allergic Encephalomyelitis in 3 studies

Research Excerpts

ExcerptRelevanceReference
"Ibudilast is a phosphodiesterase inhibitor, effective on the function of glial cells and lymphocytes, and inhibits the release of TNF-α by inflammatory cells."5.91Nose to brain delivery of ibudilast micelles for treatment of multiple sclerosis in an experimental autoimmune encephalomyelitis animal model. ( Aliomrani, M; Kazemi, M; Sharifian, A; Varshosaz, J, 2023)
"Ibudilast is a phosphodiesterase inhibitor, effective on the function of glial cells and lymphocytes, and inhibits the release of TNF-α by inflammatory cells."1.91Nose to brain delivery of ibudilast micelles for treatment of multiple sclerosis in an experimental autoimmune encephalomyelitis animal model. ( Aliomrani, M; Kazemi, M; Sharifian, A; Varshosaz, J, 2023)
"Ibudilast is a phosphodiesterase inhibitor with anti-inflammatory activity, but its effect on activated microglia in chronic neuropathic pain is poorly understood."1.48Ibudilast produces anti-allodynic effects at the persistent phase of peripheral or central neuropathic pain in rats: Different inhibitory mechanism on spinal microglia from minocycline and propentofylline. ( Asaki, T; Fujita, M; Hasegawa, M; Omachi, S; Rokushima, M; Sakaguchi, G; Shinohara, S; Tamano, R; Yogo, E; Yoneda, S, 2018)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (33.33)18.2507
2000's0 (0.00)29.6817
2010's1 (33.33)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Sharifian, A1
Varshosaz, J1
Aliomrani, M1
Kazemi, M1
Fujita, M1
Tamano, R1
Yoneda, S1
Omachi, S1
Yogo, E1
Rokushima, M1
Shinohara, S1
Sakaguchi, G1
Hasegawa, M1
Asaki, T1
Fujimoto, T1
Sakoda, S1
Fujimura, H1
Yanagihara, T1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multi-Center, Open-Label Biomarker Study to Evaluate MN-166 (Ibudilast) in Subjects With Amyotrophic Literal Sclerosis (ALS)[NCT02714036]Phase 1/Phase 235 participants (Actual)Interventional2016-05-06Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Other Studies

3 other studies available for ibudilast and Allergic Encephalomyelitis

ArticleYear
Nose to brain delivery of ibudilast micelles for treatment of multiple sclerosis in an experimental autoimmune encephalomyelitis animal model.
    International journal of pharmaceutics, 2023, May-10, Volume: 638

    Topics: Animals; Brain; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Mice; Mice, Inb

2023
Ibudilast produces anti-allodynic effects at the persistent phase of peripheral or central neuropathic pain in rats: Different inhibitory mechanism on spinal microglia from minocycline and propentofylline.
    European journal of pharmacology, 2018, Aug-15, Volume: 833

    Topics: Animals; Encephalomyelitis, Autoimmune, Experimental; Female; Humans; Hyperalgesia; Injections, Spin

2018
Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in Dark August rats.
    Journal of neuroimmunology, 1999, Mar-01, Volume: 95, Issue:1-2

    Topics: Administration, Oral; Animals; Cell Division; Disease Models, Animal; Encephalomyelitis, Autoimmune,

1999